Schizophrenia Research
Volume 42, Issue 1 , Pages 7-17 , 16 March 2000

Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients

  • Jeffrey K Yao

      Affiliations

    • VA Pittsburgh Healthcare System, Pittsburgh, PA 15206, USA
    • Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-412-365-5911; fax: +1-412-365-5917
    • ,
  • Sherry Leonard

      Affiliations

    • Departments of Psychiatry and Pharmacology, University of Colorado Health Sciences Center, Denver, CO, USA
    • ,
  • Ravinder D Reddy

      Affiliations

    • Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA

Received 25 February 1999 ,Accepted 22 May 1999.

References 

  1. Breton L, Serkiz B, Volland JP, Lepagnol J. A new rapid method for phospholipid separation by high-performance liquid chromatography with light-scattering detection. J. Chromatogr. 1989;497:243–249
  2. Christie WW. Rapid separation and quantification of lipid classes by high-performance liquid chromatography and mass (light-scattering) detection. J. Lipid Res. 1985;26:507–512
  3. Das I, Essali MA, Debelleroche J, Hirch SR. Inositol phoslipid turnover in platelet of schizophrenic patients. Prostagland. Leukotr. Essent. Fatty Acids. 1992;46:65–66
  4. Deicken RF, Merrin E, Calabrese G, Dillon W, Weiner MW, Fein G. 31Phosphorus MRSI in the frontal and parietal lobes in schizophrenia. Biol. Psychiatry. 1993;33:46A;Abstract
  5. Deicken RF, Merrin EL, Floyd TC, Weiner MW. Correlation between left frontal phospholipids and Wisconsin Card Sort Test performance in schizophrenia. Schizophr. Res. 1995;14:177–181
  6. Demisch L, Heinz K, Gerbaldo H, Kirsten R. Increased concentrations of phosphatidyl-inositol and decreased esterification of arachidonic acid into phospholipids in platelets from patients with schizoaffective disorders or atypic phasic psychoses. Prostagland. Leukotr. Essent. Fatty Acids. 1992;46:47–52
  7. Edwards E, Ashby CR, Wang RY. The effect of typical and atypical antipsychotic drugs on the stimulation of phosphoinositide hydrolysis produced by the 5-HT3 receptor agonist 2-methyl-serotonin. Brain Res. 1991;545:276–278
  8. Essali MA, Das I, Belleroche J, Hirsch SR. The platelet phosphoinositide system in schizophrenia: The effects of neuroleptic treatment. Biol. Psychiatry. 1990;28:475–487
  9. Friedel RO, Knauer G. Actions of neuroleptics on the acetylcholine-induced phospholipid effect in rat neostriatal homogenates. Psychopharmacology. 1981;20:925–930
  10. Fukuzako H, Takeuchi K, Fujimoto T, Fukuzako T, Hokazono Y, Hirakawa K, et al.  31P magnetic resonance spectroscopy of schizophrenic patients with neuroleptic-resistant positive and negative symptoms. Biol. Psychiatry. 1992;31(S):204A–205AAbstract
  11. Fukuzako H, Fukuzako T, Takeuchi K, Ohbo Y, Ueyama K, Takigawa M, et al. Phosophorus magnetic resonance spectroscopy in schizophrenia: Correlation between membrane phospholipid metabolism in temporal lobe and positive symptoms. Prog. Neuropsychopharma. Biol. Psychiary. 1996;20:629–640
  12. Gattaz WF, Köllisch M, Thuren T, Virtanen JA, Kinnunen PKJ. Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy. Biol. Psychiatry. 1987;22:421–426
  13. Gattaz WF. Phospholipase A2 in schizophrenia. Biol. Psychiatry. 1992;31:209–216
  14. Glen AIM, Glen EMT, Horrobin DF, et al.  A red cell membrane abnormality in a sub-group of schizophrenic patients: Evidence for two diseases. Schizophr. Res. 1994;12:53–61
  15. Glen AIM, Cooper SJ, Rybakowsky J, Vaddadi K, Brayshaw N, Horrobin DF. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukotr. Essent. Fatty Acids. 1996;55:9–15
  16. Horrobin DF. Schizophrenia: A biochemical disorder. Biomedicine. 1980;32:54–55
  17. Horrobin DF, Manku MS, Hillman H, Iain A, Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry. 1991;30:795–805
  18. Horrobin DF, Glen AIM, Hudson CJ. Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: The relationship between dyslexia and schizophrenia. Med. Hypotheses. 1995;45:605–613
  19. Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostagland. Leukotr. Essent. Fatty Acids. 1996;55:3–7
  20. Horrobin DF, Manku MS, Morse-Fisher N, Vaddadi KS, Courtney P, Glen AIM, et al.  Essential fatty acids in plasma phospholipids in schizophrenics. Biol. Psychiatry. 1989;25:562–568
  21. Hudson CJ, Lin A, Cogan S, Cashman F, Warsh JJ. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?. Biol. Psychiatry. 1997;41:507–513
  22. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry. 1986;143:993–997
  23. Jope RS, Song L, Powers R. Agonist-induced, GTP-dependent phosphoinositide hydrolysis in postmortem human brain membranes. J. Neurochem. 1994;62:180–186
  24. Jope RS, Song L, Li PP, Young LT, Kish SJ, Pacheco MA, et al.  The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. J. Neurochem. 1996;66:2402–2409
  25. Jope RS, Song L, Grimes CA, Pacheco MA, Dilley GE, Li X, et al.  Selective increases in phosphoinositide signaling activity and G protein levels in postmortem brain from subjects with schizophrenia or alcohol dependence. J. Neurochem. 1998;70:763–771
  26. Kaiya H, Horrobin DF, Manku MS, Morse-Fisher N. Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan. Biol. Psychiatry. 1991;30:357–362
  27. Keshaven MS, Mallinger AG, Pettegrew JW, Dippold C. Erythrocyte membrane phospholipids in psychotic patients. Psychiatr. Res. 1993;49:89–95
  28. Keshaven MS, Pettegrew JW, Ward R. Are membrane phospholipid changes in schizophrenia familial?. Biol. Psychiatry. 1993;33:45A;Abstract
  29. Leonard S, Logel J, Luthman D, Casanova M, Kirch D, Freedman R. Biological stability of MRNA isolated from human postmortem brain collections. Biol. Psychiatry. 1993;33:456–466
  30. Letter WS. A rapid method for phospholipid class separation by HPLC using an evaporative light-scattering detector. J. Liquid Chromatogr. 1992;15:253–266
  31. Li R, Wang LL, Kirch DG, Wyatt RJ, Chuang D-M. Effects of chronic nicotine and haloperidol administration on muscarinic receptor-mediated phosphoinositide turnover in rat brain slices. Psychopharmacology. 1992;109:248–250
  32. Li R, Chuang D-M, Wyatt RJ, Kirch DG. Effect of chronic haloperidol treatment on dopamine-induced inositol phosphate formation in rat brain slices. Neurochem. Res. 1994;19:673–678
  33. Mahadik SP, Mukherjee S, Correnti E, Kelkar HS, Wakade CG, Costa RM, et al.  Distribution of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophr. Res. 1994;13:239–247
  34. Nilsson A, Horrobin DF, Rosengren A, Waller L, Adlerberth A, Wilhelmsen L. Essential fatty acids and abnormal involuntary movements in the general male population: a study of men born in 1933. Prostagland. Leukotr. Essent. Fatty Acids. 1996;55:83–87
  35. Noponen M, Sanfilipo M, Samanich K, Ryer H, Ko G, Angrist B, et al.  Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry. 1993;34:641–649
  36. Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol. Psychiatry. 1997;42:1–5
  37. O'Neill C, Fowler CJ, Wiehager B, Alafuzuff I, Winblad B. Assay of a phosphatidylinositol bisphosphate phospholipase C activity in postmortem human brain. Brain Res. 1991;543:307–314
  38. Pacheco MA, Jope RS. Phosphoinositide signaling in human brain. Prog. Neurobiol. 1996;50:255–273
  39. Peet M, Laughame JDE, Rangarajan N, Horrobin DF, Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J. Psychiatr. Res. 1995;29:227–232
  40. Peet M, Laugharne JDE, Mellor J, Ramchand CN. Essential fatty acid deficiency in eyrthrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostagland. Leukotr. Essent. Fatty Acids. 1996;55:71–75
  41. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG, et al.  Alterations in brain high energy phosphate and membrane phospholipid metabolism in first episode drug naı̈ve schizophrenics. Arch. Gen. Psychiatry. 1991;48:563–568
  42. Pettegrew JW, Keshaven MS, Minshew NJ. 31P nuclear magnetic resonance spectroscopy: Neurodevelopment and schizophrenia. Schizophr. Bull. 1993;19:335–353
  43. Reddy, R.D., Yao, J.K., in press. Schizophrenia: Role of oxidative stress and essential fatty acids. In: Temple and Basn (Eds.), Antioxidants and Disease.
  44. Rotrosen J, Wolkin A. Phospholipid and prostaglandin hypotheses of schizophrenia. In:  Meltzer NY editors. Psychopharmacology. The Third Generation on Progress. New York: Raven Press; 1987;p. 759–764
  45. Shioiri T, Kato T, Inubushi T, Murashita J, Takahashi S. Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatr. Res. 1994;55:223–235
  46. Stanley JA, Williamson PC, Drost DJ, Carr T, Rylett RJ, Morrison-Stewart S, et al.  Membrane phospholipid metabolism and schizophrenia: an in vivo 31P MR spectroscopy study. Schizophr. Res. 1994;13:209–215
  47. Svennerholm L, Bostrom K, Helander CG, Jungbjer B. Membrane lipids in the aging human brain. J. Neurochem. 1991;56:2051–2059
  48. Tacconi MT, Calzi F, Salmona M. Brain lipids and diet. In:  Hillbrand M,  Spitz TS editor. Lipids, Health and Behavior. Washington, DC: American Psychological Association; 1997;p. 197–226
  49. Vaddadi KS, Courtney P, Gillard CJ, Manku MS, Horrobin DF. A double blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatr. Res. 1989;27:313–323
  50. Vaddadi KS. Dyskinesias and their treatment with essential fatty acids: a review. Prostagland. Leukotr. Essent. Fatty Acids. 1996;55:89–94
  51. Vijayaraghavan S, Huang B, Blumenthal EM, Berg DK. Arachidonic acid as a possible negative feedback inhibitor of nicotinic acetylcholine receptors on neurons. J. Neurosci. 1995;15:3679–3687
  52. Wallace MA, Claro E. Transmembrane signalling through phospholipase C in human cortical membranes. Neurochem. Res. 1993;18:139–145
  53. Williamson P, Drost D, Stanley J, Carr T, Morrison S, Merskey H. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. Arch. Gen. Psychiatr. 1991;48:578;Letter
  54. Yao JK, Yasei P, van Karnmen DP. Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostagland. Leukotr. Essent. Fatty Acids. 1992;46:39–46
  55. Yao JK, van Kammen DP. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity. Schizophr. Res. 1994;11:209–216
  56. Yao JK, van Kammen DP, Gurklis J. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures. Schizophr. Res. 1994;13:227–232
  57. Yao JK, van Kammen DP, Gurklis J, Peters JL. Platelet aggregation and secretion in schizophrenia. Psychiatr. Res. 1994;54:13–24
  58. Yao JK, van Kammen DP, Welker JA. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr. Res. 1994;13:217–226
  59. Yao JK, van Kammen DP. Incorporation of [3H]arachidonic acid into platelet phospholipids of patients with schizophrenia. Prostagland. Leukotr. Essent. Fatty Acids. 1996;55:21–26
  60. Yao JK, van Kammen DP, Gurklis J. Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia. Psychiatr. Res. 1996;60:11–21
  61. Yao JK, van Kammen DP, Moss HB, Sokulski DE. A decreased serotonergic responsivity in platelets of unmedicated patients with schizophrenia. Psychiatr. Res. 1996;63:123–132
  62. Zubenko GS, Cohen BM. A cell membrane correlate of tardive dyskinesia in patients treated with phenothiazines. Psychopharmacology. 1986;88:230–236

PII: S0920-9964(99)00095-X

Schizophrenia Research
Volume 42, Issue 1 , Pages 7-17 , 16 March 2000

Article Tools

* Image Usage & Resolution